NETRAMARK AND WORLDWIDE CLINICAL TRIALS ANNOUNCE AGREEMENT TO TRANSFORM CLINICAL TRIAL DESIGN WITH AI-POWERED PRECISION
NetraMark Holdings (OTCQB: AINMF) has announced a global partnership with Worldwide Clinical Trials to enhance clinical trial design using AI technology. The collaboration integrates NetraMark's proprietary NetraAI platform into Worldwide's service offerings, initially focusing on Phase 2 neuroscience and oncology trials, with plans to expand across all therapeutic areas.
The partnership combines Worldwide's three decades of clinical execution excellence and 11 consecutive CRO Leadership Awards with NetraMark's advanced AI solution. The integration aims to optimize clinical trials by identifying hidden patient subpopulations within complex datasets, improving trial efficiency, and delivering regulatory-aligned insights.
Key benefits include accelerated development timelines, refined patient stratification, reduced placebo response variability, and enhanced trial power. The collaboration is expected to enable more informed protocol development, faster decision-making, and improved patient targeting, ultimately leading to fewer required patients per trial, reduced timelines, and lower costs for sponsors.
NetraMark Holdings (OTCQB: AINMF) ha annunciato una partnership globale con Worldwide Clinical Trials per migliorare la progettazione degli studi clinici utilizzando la tecnologia AI. La collaborazione integra la piattaforma proprietaria di NetraMark, NetraAI, nei servizi offerti da Worldwide, concentrandosi inizialmente sugli studi di neuroscienze e oncologia di Fase 2, con piani di espansione in tutte le aree terapeutiche.
La partnership combina i trent'anni di eccellenza nell'esecuzione clinica di Worldwide e 11 premi consecutivi di Leadership nel CRO con la soluzione avanzata di AI di NetraMark. L'integrazione mira a ottimizzare gli studi clinici identificando sottogruppi di pazienti nascosti all'interno di set di dati complessi, migliorando l'efficienza degli studi e fornendo approfondimenti allineati con le normative.
I principali vantaggi includono tempi di sviluppo accelerati, stratificazione dei pazienti affinata, riduzione della variabilità nella risposta al placebo e potenziamento della potenza degli studi. Si prevede che la collaborazione consenta uno sviluppo di protocolli più informato, decisioni più rapide e un targeting dei pazienti migliorato, portando infine a un minor numero di pazienti richiesti per studio, a tempi ridotti e a costi inferiori per gli sponsor.
NetraMark Holdings (OTCQB: AINMF) ha anunciado una asociación global con Worldwide Clinical Trials para mejorar el diseño de ensayos clínicos utilizando tecnología de IA. La colaboración integra la plataforma propietaria de NetraMark, NetraAI, en la oferta de servicios de Worldwide, centrándose inicialmente en ensayos de neurología y oncología de Fase 2, con planes de expansión a todas las áreas terapéuticas.
La asociación combina tres décadas de excelencia en la ejecución clínica de Worldwide y 11 premios consecutivos de Liderazgo en CRO con la solución avanzada de IA de NetraMark. La integración tiene como objetivo optimizar los ensayos clínicos identificando subpoblaciones de pacientes ocultas dentro de conjuntos de datos complejos, mejorando la eficiencia de los ensayos y ofreciendo información alineada con las regulaciones.
Los principales beneficios incluyen plazos de desarrollo acelerados, estratificación de pacientes refinada, reducción de la variabilidad en la respuesta al placebo y aumento del poder del ensayo. Se espera que la colaboración permita un desarrollo de protocolos más informado, una toma de decisiones más rápida y un mejor enfoque en los pacientes, lo que en última instancia conducirá a un menor número de pacientes requeridos por ensayo, plazos reducidos y menores costos para los patrocinadores.
NetraMark Holdings (OTCQB: AINMF)는 Worldwide Clinical Trials와의 글로벌 파트너십을 발표하여 AI 기술을 활용한 임상 시험 설계를 향상시키고자 합니다. 이 협력은 NetraMark의 독점 플랫폼인 NetraAI를 Worldwide의 서비스 제공에 통합하며, 초기에는 2상 신경과학 및 종양학 시험에 집중하고, 모든 치료 분야로 확장할 계획입니다.
이 파트너십은 Worldwide의 30년 임상 실행 우수성과 11년 연속 CRO 리더십 상을 NetraMark의 고급 AI 솔루션과 결합합니다. 통합의 목표는 복잡한 데이터 세트 내에서 숨겨진 환자 하위 집단을 식별하여 임상 시험을 최적화하고 시험 효율성을 개선하며 규제에 맞는 통찰력을 제공하는 것입니다.
주요 이점으로는 개발 일정 가속화, 세분화된 환자 stratification, 위약 반응 변동성 감소 및 시험 능력 향상이 포함됩니다. 이 협력은 보다 정보에 기반한 프로토콜 개발, 더 빠른 의사 결정 및 개선된 환자 타겟팅을 가능하게 하여 궁극적으로 시험당 필요한 환자 수를 줄이고, 일정 단축 및 후원자 비용 절감으로 이어질 것으로 예상됩니다.
NetraMark Holdings (OTCQB: AINMF) a annoncé un partenariat mondial avec Worldwide Clinical Trials pour améliorer la conception des essais cliniques en utilisant la technologie IA. La collaboration intègre la plateforme propriétaire NetraAI de NetraMark dans les offres de services de Worldwide, en se concentrant initialement sur les essais de neurosciences et d'oncologie de Phase 2, avec des plans d'expansion dans tous les domaines thérapeutiques.
Ce partenariat combine trois décennies d'excellence dans l'exécution clinique de Worldwide et 11 prix consécutifs de Leadership CRO avec la solution IA avancée de NetraMark. L'intégration vise à optimiser les essais cliniques en identifiant des sous-populations de patients cachées au sein de jeux de données complexes, en améliorant l'efficacité des essais et en fournissant des informations conformes aux réglementations.
Les principaux avantages incluent des délais de développement accélérés, une stratification des patients affinée, une réduction de la variabilité de la réponse au placebo et un renforcement de la puissance des essais. La collaboration devrait permettre un développement de protocoles plus informé, une prise de décision plus rapide et un ciblage des patients amélioré, conduisant finalement à un nombre réduit de patients requis par essai, à des délais réduits et à des coûts moindres pour les sponsors.
NetraMark Holdings (OTCQB: AINMF) hat eine globale Partnerschaft mit Worldwide Clinical Trials angekündigt, um das Design klinischer Studien mithilfe von KI-Technologie zu verbessern. Die Zusammenarbeit integriert die proprietäre NetraAI-Plattform von NetraMark in die Dienstleistungsangebote von Worldwide, wobei zunächst der Fokus auf Phase-2-Studien in der Neurowissenschaft und Onkologie liegt, mit Plänen zur Ausweitung auf alle therapeutischen Bereiche.
Die Partnerschaft kombiniert die drei Jahrzehnte an klinischer Ausführungsexzellenz und 11 aufeinanderfolgende CRO Leadership Awards von Worldwide mit der fortschrittlichen KI-Lösung von NetraMark. Ziel der Integration ist es, klinische Studien zu optimieren, indem versteckte Patientensubpopulationen innerhalb komplexer Datensätze identifiziert werden, die Effizienz der Studien verbessert und regulatorisch konforme Einblicke geliefert werden.
Zu den wichtigsten Vorteilen gehören beschleunigte Entwicklungszeiträume, verfeinerte Patientensegmentierung, reduzierte Variabilität der Placeboantwort und erhöhte Studienkraft. Die Zusammenarbeit wird voraussichtlich eine informiertere Protokollentwicklung, schnellere Entscheidungsfindung und verbesserte Patientenzielgruppen ermöglichen, was letztendlich zu einer geringeren Anzahl benötigter Patienten pro Studie, verkürzten Zeitrahmen und geringeren Kosten für die Sponsoren führen wird.
- Strategic partnership with established CRO expands market reach
- Integration into Worldwide's service offerings provides direct commercialization pathway
- Technology application across multiple trial phases indicates scalability
- Partnership expected to reduce trial costs and timelines for sponsors
- Initial implementation to specific therapeutic areas
- Success of AI integration and adoption by sponsors yet to be proven
This agreement unites Worldwide's three decades of clinical execution excellence—recognized with 11 consecutive CRO Leadership Awards—with NetraMark's advanced NetraAI platform, an explainable AI solution designed to optimize clinical trials by uncovering hidden patient subpopulations within complex datasets. Leveraging Worldwide's global clinical operations, scientific rigor, and therapeutic expertise alongside NetraMark's proprietary machine learning platform, this collaboration enhances trial efficiency and delivers regulatory-aligned insights from even the most complex datasets.
Under this agreement, NetraMark's AI technology will initially be used for Phase 2 (neuroscience and oncology clinical trials) and select Phase 3 clinical trials conducted by Worldwide, however, broader availability will be made to all Worldwide sponsors across all therapeutic areas and trial phases. As part of the collaboration, and to streamline workflow for sponsors, NetraMark's NetraAI will be incorporated into Worldwide's offerings as a dedicated solution that underscores both companies' commitment to innovation, precision, and advancing clinical trial success.
Through this integration, Worldwide strengthens its ability to accelerate development timelines, refine patient stratification, reduce placebo response variability, and enhance overall trial power. Together, Worldwide and NetraMark aim to redefine how trials are designed and executed—enabling more informed protocol development, faster decision-making, and improved patient targeting through the use of AI.
"With this agreement, our goal is to unlock the full potential of AI to reshape the future of clinical development," said George Achilleos, CEO of NetraMark. "By integrating NetraAI with Worldwide's global clinical infrastructure, we're enabling sponsors to better understand patient response dynamics, reduce placebo variability, and improve the likelihood of regulatory success. Worldwide's new service offering will deliver a redefined standard for precision and speed in trials."
"At Worldwide, we are dedicated to partnering with sponsors for the most efficient and effective path to bring life-changing therapies to market," said Dave Bowser, Chief Operating Officer at Worldwide Clinical Trials. "By integrating NetraMark's technology into our clinical trial design, we can identify the patients most likely to drive positive trial outcomes, leading to fewer required patients per trial, reduced timelines, lower costs, and ultimately increase success rates for our sponsors. This partnership represents a significant step forward in precision medicine and patient-centric trial optimization."
Together, Worldwide and NetraMark are ushering in a new era of explainable AI in clinical research—one that is expected to enable more personalized therapies to reach patients faster and more reliably.
About Worldwide Clinical Trials
Worldwide Clinical Trials (Worldwide) is a full-service global contract research organization (CRO) that works in partnership with biotechnology and pharmaceutical companies to create customized solutions that advance new medications – from discovery to reality. Worldwide's capabilities include bioanalytical laboratory services, Phase I-IV clinical trials, and post-approval and real-world evidence studies – all powered by an accessible team of clinicians, scientists, and researchers who bring first-hand expertise and a collaborative, personalized approach to each clinical program. Worldwide is therapeutically focused on neuroscience, oncology, rare diseases, and cardiometabolic and inflammatory disease. Its global footprint spans over 60 countries with more than 3,500 team members. For more information, visit www.worldwide.com.
About NetraAI
In contrast to other AI-based methods, NetraAI is uniquely engineered to include focus mechanisms that separate small datasets into explainable and unexplainable subsets. Unexplainable subsets are collections of patients that can lead to suboptimal overfit models and inaccurate insights due to poor correlations with the variables involved. The NetraAI uses the explainable subsets to derive insights and hypotheses (including factors that influence treatment and placebo responses, as well as adverse events) providing the potential to increase the chances of a clinical trial success. Many other AI methods lack these focus mechanisms and assign every patient to a class, often leading to "overfitting" which drowns out critical information that could have been used to improve a trial's chance of success.
About NetraMark
NetraMark is a company focused on being a leader in the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the pharmaceutical industry. Its product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows NetraMark to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that NetraMark can work with much smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment.
For further details on the Company please see the Company's publicly available documents filed on the System for Electronic Document Analysis and Retrieval+ (SEDAR+).
Forward-Looking Statements
This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation including statements regarding the potential use of NetraMark's AI solutions to drive intelligent, patient-centric clinical trial optimization, the optimization of clinical trials by uncovering hidden patient subpopulations, the application of NetraMark's AI technology in Phase 2 and select Phase 3 clinical trials, the integration of NetraMark's AI as a dedicated solution to advance clinical trial success, Worldwide's ability to accelerate development timelines, refine patient stratification, reduce placebo response variability, and enhance overall trial power, the potential for NetraMark's partnership with Worldwide to redefine clinical trial design and execution, unlock the full potential of AI in clinical development, improve the likelihood of regulatory success, set new standards for precision and speed in trials, and identify patients likely to drive positive trial outcomes, which are based upon NetraMark's current internal expectations, estimates, projections, assumptions and beliefs, and views of future events. Forward-looking information can be identified by the use of forward-looking terminology such as "expect", "likely", "may", "will", "should", "intend", "anticipate", "potential", "proposed", "estimate" and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions "may", "would" or "will" happen, or by discussions of strategy. Forward-looking information includes estimates, plans, expectations, opinions, forecasts, projections, targets, guidance, or other statements that are not statements of fact. The forward-looking statements are expectations only and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results of the Company or industry results to differ materially from future results, performance or achievements including that the agreement or specific work orders may be terminated in certain circumstances by either party, a clinical trial sponsor may opt not to use the NetraMark AI solution and payment to Netramark is made upon issuance of its deliverable upon completion of a clinical trial. Any forward-looking information speaks only as of the date on which it is made, and, except as required by law, NetraMark does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise. New factors emerge from time to time, and it is not possible for NetraMark to predict all such factors.
When considering these forward-looking statements, readers should keep in mind the risk factors and other cautionary statements as set out in the materials we file with applicable Canadian securities regulatory authorities on SEDAR+ at www.sedarplus.ca including our Management's Discussion and Analysis for the year ended September 30, 2024. These risk factors and other factors could cause actual events or results to differ materially from those described in any forward-looking information.
The CSE does not accept responsibility for the adequacy or accuracy of this release.
View original content to download multimedia:https://www.prnewswire.com/news-releases/netramark-and-worldwide-clinical-trials-announce-agreement-to-transform-clinical-trial-design-with-ai-powered-precision-302420221.html
SOURCE NetraMark Holdings Inc.
FAQ
What are the initial focus areas for NetraMark's AINMF AI technology in the Worldwide Clinical Trials partnership?
How will the AINMF and Worldwide Clinical Trials partnership improve clinical trial efficiency?
What specific technology is AINMF implementing in this clinical trial partnership?
What are the expected benefits for sponsors using AINMF's AI technology in clinical trials?
